Comprehensive Management of Pediatric Type 1 Diabetes Mellitus: A Review of Physician, Social Work, and Nursing Roles
DOI:
https://doi.org/10.22399/ijcesen.4424Keywords:
Pediatric Type 1 Diabetes Mellitus, comprehensive management, multidisciplinary approach, physician role, insulin therapy, glycemic controlAbstract
Pediatric Type 1 Diabetes Mellitus (T1DM) presents a unique set of challenges that necessitate a comprehensive management strategy involving a multidisciplinary approach. Physicians play a critical role in diagnosing the condition, prescribing appropriate insulin regimens, and monitoring glycemic control to minimize complications. They work to ensure that children and their families understand the importance of regular blood glucose monitoring and the administration of insulin. Additionally, physicians coordinate care by collaborating with other healthcare professionals, including dietitians, social workers, and nurses, to create an individualized management plan that addresses the medical, emotional, and social needs of the child. This coordinated approach is essential for optimizing health outcomes and facilitating a better quality of life for pediatric patients. The role of social work and nursing in the management of pediatric T1DM cannot be overstated. Social workers provide psychosocial support to children and their families, helping them navigate the emotional challenges associated with chronic illness. This support may include counseling, advocacy, and education on coping strategies, which are crucial for fostering resilience in young patients. Nurses, on the other hand, play a vital role in the day-to-day management of diabetes care—educating patients about self-management techniques, conducting routine check-ups, and monitoring for potential complications. Both social workers and nurses contribute to a holistic approach that empowers families, ensuring they have the resources, knowledge, and emotional support necessary to manage diabetes effectively and efficiently.
References
1. Subramanian S, Baidal D. The Management of Type 1 Diabetes. South Dartmouth (MA): Endotext; 2000.
2. Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications. Diabetes Metab J. 2019;43:383–397.
3. Zahalka SJ, Abushamat LA, Scalzo RL, Reusch JE. The Role of Exercise in Diabetes. South Dartmouth (MA): Endotext; 2000.
4. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract. 2011;17:271–280.
5. Nallicheri A, Mahoney KM, Gutow HA, Bellini N, Isaacs D. Review of automated insulin delivery systems for type 1 diabetes and associated time in range outcomes. touchREV Endocrinol. 2022;18:27–34.
6. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018;41:2026–2044.
7. Teló GH, Dougher CE, Volkening LK, Katz ML, Laffel LM. Predictors of changing insulin dose requirements and glycaemic control in children, adolescents and young adults with type 1 diabetes. Diabet Med. 2018;35:1355–1363.
8. Menon AP, Moreno B, Meraviglia-Crivelli D, et al. Modulating T cell responses by targeting CD3. Cancers (Basel) 2023;15:1189.
9. Karakuş KE, Sakarya S, Yeşiltepe Mutlu G, et al. Benefits and drawbacks of continuous glucose monitoring (CGM) use in young children with type 1 diabetes: a qualitative study from a country where the CGM is not reimbursed. J Patient Exp. 2021;8.
10. van Duinkerken E, Snoek FJ, de Wit M. The cognitive and psychological effects of living with type 1 diabetes: a narrative review. Diabet Med. 2020;37:555–563.
11. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
12. Saleem F, Sharma A. NPH Insulin. Treasure Island (FL): StatPearls Publishing; 2024.
13. Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne) 2017;8:343.
14. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S66–S76.
15. Kopan C, Tucker T, Alexander M, Mohammadi MR, Pone EJ, Lakey JR. Approaches in immunotherapy, regenerative medicine, and bioengineering for type 1 diabetes. Front Immunol. 2018;9:1354.
16. Kalra S, Jena BN, Yeravdekar R. Emotional and psychological needs of people with diabetes. Indian J Endocrinol Metab. 2018;22:696–704.
17. Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015;42:42–60.
18. Galasko GT. Insulin, oral hypoglycemics, and glucagon. In: Pharmacology and Therapeutics for Dentistry (Seventh Edition). Maryland Heights (MO): Mosby; 2017. pp. 437–445.
19. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10:98–115.
20. Esposito S, Santi E, Mancini G, et al. Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes. J Transl Med. 2018;16:176.
21. Zecevic-Pasic L, Tihic-Kapidzic S, Hasanbegovic S, Begovic E, Gojak R, Dzananovic N. Presence of type 1 diabetes-related autoantibodies in pediatric population in Bosnia and Herzegovina. Mater Sociomed. 2023;35:190–195.
22. Vora J, Cariou B, Evans M, et al. Clinical use of insulin degludec. Diabetes Res Clin Pract. 2015;109:19–31.
23. Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes Spectr. 2019;32:194–204.
24. Donnor T, Sarkar S. Insulin-Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy. South Dartmouth (MA): Endotext; 2000.
25. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. Treasure Island (FL): StatPearls Publishing; 2024.
26. Sageshima J, Ciancio G, Chen L, Burke GW. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biol Targets Ther. 2009;3:319–336.
27. Kazda CM, Bue-Valleskey JM, Chien J, et al. Novel once-weekly basal insulin Fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes. Diabetes Care. 2023;46:1052–1059.
28. Chendke GS, Kharbikar BN, Ashe S, et al. Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space. Bioeng Transl Med. 2023;8.
29. Schmeltz L, Metzger B. Diabetes/syndrome X. In: Comprehensive Medicinal Chemistry II. Vol. 6. Amsterdam: Elsevier; 2007. pp. 417–458.
30. Yao PY, Ahsun S, Anastasopoulou C, Tadi P. Insulin Pump. Treasure Island (FL): StatPearls Publishing; 2024.
31. EL-Mohandes N, Yee G, Bhutta BS, Huecker MR. Pediatric Diabetic Ketoacidosis. Treasure Island (FL): StatPearls Publishing; 2024.
32. Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. Treasure Island (FL): StatPearls Publishing; 2024.
33. Los E, Wilt AS. Type 1 Diabetes in Children. Treasure Island (FL): StatPearls Publishing; 2024.
34. Zakir M, Ahuja N, Surksha MA, et al. Cardiovascular complications of diabetes: from microvascular to macrovascular pathways. Cureus. 2023;15.
35. Kandemir N, Vuralli D, Ozon A, et al. Epidemiology of type 1 diabetes mellitus in children and adolescents: a 50-year, single-center experience. J Diabetes. 2024;16.
36. Lohiya NN, Kajale NA, Lohiya NN, Khadilkar VV, Gondhalekar K, Khadilkar A. Diabetes distress in Indian children with type 1 diabetes mellitus and their mothers. J Pediatr Endocrinol Metab. 2021;34:209–216.
37. Monnier L, Owens DR, Bolli GB. The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation. Diabetes Metab. 2016;42:77–79.
38. Doupis J, Festas G, Tsilivigos C, Efthymiou V, Kokkinos A. Smartphone-based technology in diabetes management. Diabetes Ther. 2020;11:607–619.
39. Lucier J, Weinstock RS. Type 1 Diabetes. Treasure Island (FL): StatPearls Publishing; 2024.
40. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.
41. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21–39.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
